Purchase this article with an account.
Nobuhiro Nagai, Saaya Saijo, Yuanhui Song, Hirokazu Kaji, Matsuhiko Nishizawa, Toshiaki Abe; A Refillable Drug Delivery Device to the Retina. Invest. Ophthalmol. Vis. Sci. 2018;59(9):5704.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the ability of refilling the drug in vitro and in vivo and drug delivery to the retina of the device consisting of a silicone reservoir and an injectable gelatin/chitosan gel as a drug formulation.
The silicone reservoir was fabricated with polydimethylsiloxane using a computer-aided design and manufacturing to have micro-pores at a releasing side. The drug was injected and formulated in the reservoir by in situ crosslinking of gelatin/chitosan gel with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, hydrochloride. The in vitro release of fluorescein isothiocyanate–dextran 150 kDa (FD150) was studied. The in vivo release of FD150 in rabbits was evaluated by observing the cryosection of the eye and measuring the fluorescent intensity of retina homogenates 1 and 4 weeks after treatment.
The in vitro release profile showed a constant release of FD150 with decreasing release rate for 4 weeks. After reinjecting the FD150-loaded gel in the reservoir, the same release profile as the first injection was observed. The in vivo study showed that FD150 was detected in the retina 1 and 4 weeks after treatment. The gel could be injected in the device implanted on the sclera.
The refillable drug delivery device is a promising tool to administer drug over the long lifetime of the device by reinjecting the drug.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only